HCC CONNECT

📺 Catch the highlights from the new #HCC podcast with Dr Rachna Shroff and the Oncology Brothers, Drs Rohit & Rahul Gosain, as they discuss the use of #IO in unresectable HCC and explore the most recent clinical trial data. Full podcast is available at https://lnkd.in/enJvXkYA #MedEd Supported by an independent educational grant from AstraZeneca

🎉 Our new podcast is live! In the first of this 4-part podcast series, Dr Rachna Shroff and the Oncology Brothers, Drs Rohit and Rahul Gosain, explore the use of immunotherapy (IO) in unresectable hepatocellular carcinoma (uHCC). 💡 Experts provide an overview of current systemic treatment options for 1st line uHCC, discussing the role of IO and IO-based combinations, along with emerging therapies and the latest clinical data. 📹 Video podcast with subtitles, available to watch on YouTube: https://ow.ly/VkHq50Uhlfb 🎧 Audio podcast - available to listen to on: Spotify - https://ow.ly/coEI50Uhlfg Apple - https://ow.ly/X1Ic50Uhlff 📄 Download the transcript on our website: https://ow.ly/ujUP50Uhlfe Endorsed by Digestive Cancers Europe & Blue Faery: The Adrienne Wilson Liver Cancer Association #MedEd #HCC #IO AstraZeneca has provided a sponsorship grant towards this independent programme.

🎉 New video podcast coming soon! 💡 In episode 2 international experts Dr Arndt Vogel and Dr Lorenza Rimassa will discuss 2nd line treatment for advanced HCC and when to switch after progression on 1st line systemic treatment Follow HCC CONNECT to stay updated on its release, and check out our other independent medical education programmes👇 https://ow.ly/wMti50U90iH #MedEd #HCC #IO

⚠️ New video podcast coming soon! The first episode in our new series on HCC management focuses on the safety and efficacy of IO and IO combinations in unresectable HCC. 💡 Led by international expert Dr Rachna Shroff and moderated by the Oncology Brothers Follow HCC CONNECT to stay updated on its release, and check out our other independent medical education programmes👇 https://ow.ly/sPAr50U90pW #MedEd #HCC #IO

The COR2ED YouTube channel has surpassed 3000 subscribers 👏👏👏 #MedicalEducation

🎉 Abstracts for the 75th AASLD Liver Meeting have been released! We've made a list of some that we're looking forward to, look them up below: https://ow.ly/CgST50U0WzI 🗓️ November 15th - 19th, 2024 📍 San Diego, CA Follow HCC CONNECT for more updates & check out our medical education👇 https://ow.ly/PjRe50U0Wp4 #MedEd #TLM24 #HCC American Association for the Study of Liver Diseases (AASLD)

✅ Results from the HIMALAYA study showed STRIDE (single tremelimumab regular interval durvalumab) demonstrated an unprecedented 5-year survival rate. There were no additional serious treatment-related adverse related events (TRAEs) in the extended follow up. Do you know how many patients were alive with STRIDE at 5 years? Find out in the ESMO 2024 video update from Dr Richard Finn👇 https://ow.ly/YwXA50TKUcw #MedEd #HCC #IO

❓Have you read the most recent Global Liver Institute Liver Cancer News article? Highlights include: ➡️ Women with Liver Cancer Less Likely than Men to Receive Liver Transplant ➡️ The First and Only Subcutaneous Anti-PD-(L)1 Cancer Immunotherapy has been approved ➡️ Direct-Acting Antivirals: A Powerful Tool to Prevent Liver Cancer ➡️ Single-Fraction Radiotherapy Improves Pain in Hepatic Cancer Read the full article👇 https://ow.ly/UNrj50TKTGE #MedEd #HCC #LiverCancerAwarenessMonth

❌ Results from IMbrave050 do not support atezolizumab + bevacizumab as an adjuvant therapy for all high-risk HCC. Initial RFS benefit with atezolizumab + bevacizumab versus active surveillance was not sustained. ✅ Safety profile of atezolizumab + bevacizumab remained manageable and consistent with each agent and underlying HCC. Do you know the key HCC data from ESMO 2024? Find out in the video update by Dr Richard Finn here, including key takeaways from HIMALAYA, CheckMate 9DW & LEAP-012👇 https://ow.ly/6pe250TKmIv #MedEd #HCC #IO

🚨 Abstracts for the ILCA Annual Conference have been released! We've made a list of some that we're looking forward to, look them up below: https://ow.ly/UN8Z50TKvTG 🗓️ 17th - 19th October, 2024 📍 Toronto, Canada Follow HCC CONNECT for more updates & check out our medical education👇 https://ow.ly/sgAb50TKvTK #MedEd #HCC #ILCA24 International Liver Cancer Association (ILCA)